Phase 2 Open-Label, Multi-Center Study to Evaluate the Safety and Efficacy of Sunitinib Malate in Combination With AMG 386 as First Line or Second Line Therapy for Subjects With Metastatic Renal Cell Carcinoma
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 03 Apr 2018
At a glance
- Drugs Sunitinib (Primary) ; Trebananib (Primary)
- Indications Renal cell carcinoma
- Focus Adverse reactions
- Sponsors Amgen
- 26 Mar 2018 Planned End Date changed from 29 Mar 2018 to 30 Nov 2018.
- 02 Oct 2017 Planned End Date changed from 29 Sep 2017 to 29 Mar 2018.
- 10 Jun 2017 Biomarkers information updated